X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CNM-Au8 is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism. It is currently in development as a disease-modifying treatment for people living with amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
CNM-Au8 is a ROS inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with amyotrophic lateral sclerosis.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
The funding will support an Expanded Access Protocol for the Company’s investigational drug, CNM-Au8, an investigational first-in-class therapy, in amyotrophic lateral sclerosis (ALS).
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: $45.1 million Upfront Cash: Undisclosed
Deal Type: Funding October 05, 2023
Details:
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
Clene intends to use the net proceeds to fund the clinical development of its lead drug candidate, CNM-Au8, an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vivo Capital
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 21, 2023
Details:
Clene intends to use the net proceeds to fund the clinical development of its lead drug candidate, CNM-Au8, an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 16, 2023
Details:
Clene intends to use the net proceeds to fund the clinical development of its lead drug candidate, CNM-Au8, an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2023
Details:
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
